Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 203-777-6 | CAS number: 110-54-3
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Neurotoxicity
Administrative data
Description of key information
LOAEC (sub-chronic, rat; conduction velocity) = (10560 mg/m3) 3000 ppm
Occupational epidemiology data describing neurotoxicity effects in humans are avaible for n-hexane and have been extensively reviewed by WHO, ATSDR, and U. S. EPA.
Key value for chemical safety assessment
Effect on neurotoxicity: via oral route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Effect on neurotoxicity: via inhalation route
Link to relevant study records
- Endpoint:
- neurotoxicity: sub-chronic inhalation
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 1980
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: This study is classified as reliable with restrictions because although a GLP statement was provided limited data on methods and guidelines were reported. The study seemed to be well-conducted.
- Qualifier:
- no guideline followed
- Principles of method if other than guideline:
- 7 rats were exposed to 3000 ppm of hexane vapors for 12 hrs a day for 16 weeks. Body weights and conduction velocity of the peripheral nerve of the tail was measured at 0, 4, 8, 12 and 16 weeks. At the end of the exposure period, two animals were sacrificed and the nerve tissue examined.
- GLP compliance:
- yes
- Limit test:
- yes
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Weight at study initiation: 308 +/- 18 g
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 23.5-24.5 - Route of administration:
- inhalation: vapour
- Details on exposure:
- GENERATION OF TEST ATMOSPHERE / CHAMBER DESCRIPTION
- Temperature, humidity, pressure in air chamber: 23.5-24.5 degree C, 41-61% humidity
TEST ATMOSPHERE
- Brief description of analytical method used: gas detector measurements were taken daily, liquid chromatography measurements were taken twice weekly
- Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- gas detector measurements were taken daily, liquid chromatography measurements were taken twice weekly
- Duration of treatment / exposure:
- 16 weeks
- Frequency of treatment:
- daily, 12 hrs per day
- Remarks:
- Doses / Concentrations:
3000 ppm
Basis:
no data - No. of animals per sex per dose:
- 7
- Control animals:
- yes, sham-exposed
- Observations and clinical examinations performed and frequency:
- BODY WEIGHT: Yes
- Time schedule for examinations: 0, 4, 8, 12, and 16 weeks after start of exposure
OTHER: The conduction velocity of the peripheral nerve of the tail was measured at 0, 4, 8, 12 and 16 weeks - Sacrifice and (histo)pathology:
- HISTOPATHOLOGY: Yes, 2 rats were sacrificed at the end of 16 weeks, and their gastrocnemius and soleus muscles, dorsal trunk of the tail nerve, and the tibial nerve examined.
- Clinical signs:
- effects observed, treatment-related
- Mortality:
- mortality observed, treatment-related
- Body weight and weight changes:
- not examined
- Food consumption and compound intake (if feeding study):
- not examined
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Clinical biochemistry findings:
- not examined
- Behaviour (functional findings):
- effects observed, treatment-related
- Gross pathological findings:
- not examined
- Neuropathological findings:
- effects observed, treatment-related
- Other effects:
- not specified
- Details on results:
- CLINICAL SIGNS AND MORTALITY
Two animals died during the study. One animal died 1 day before the end of the exposure period, and one animal died three days before the end of the exposure period.
BODY WEIGHT AND WEIGHT GAIN
Body weight gain was significantly reduced at 4 weeks after start of exposure, and remained depressed for the rest of the experiment.
NEUROBEHAVIOUR
Unsteady gait was observed in one animal at 10 weeks exposure, and in 4 animals at 12 weeks. 2 animals at this time point also showed foot drop. At 16 weeks exposure, the five surviving rats had unsteady gait, and two had foot drop. All animals had muscular atrophy at this time point.
HISTOPATHOLOGY: NON-NEOPLASTIC
There were paranodal swellings in the myelinated fibers of the tibial nerve and dorsal trunk of the tail nerve. There were an excessive number of neurofilaments, vesicles, multivesicular bodies, mitochondria, myelin figures, and dense bodies in the paranodal axoplasm and no neurotubules. Denervated neuromuscular junctions in the muscles were observed. Muscle fibers were of irregular shape and size, and had an increased number of nuclei, and had disordered myofilaments, zig-zagging of the z-band, and invaginations of the plasma membrane.
OTHER FINDINGS
The motor nerve conduction velocity (MCV) was significantly less than controls by 4 weeks of exposure. MCVs could not be measured in 2 animals after 16 weeks due to nerve damage. Distal latencies (DL) were significantly prolonged after 4 weeks of exposure, and could not be measured in 2 aminals at 16 weeks of exposure. - Key result
- Dose descriptor:
- LOAEC
- Effect level:
- 3 000 ppm
- Sex:
- male
- Basis for effect level:
- other: reduced body weight gain
- Remarks on result:
- other:
- Conclusions:
- The LOAEC for sub-chronic exposure to hexane vapors was 3000 ppm (10560 mg/m^3) based on reduced body weight gain, mortality and neurological effects.
- Executive summary:
In this study, 7 rats were exposed to 3000 ppm of hexane vapors for 12 hrs a day for 16 weeks. Body weights and conduction velocity of the peripheral nerve of the tail was measured at 0, 4, 8, 12 and 16 weeks. At the end of the exposure period, two animals were sacrificed and the nerve tissue examined. Two animals died before the end of the exposure period. All animals showed reduced weight gain after 4 weeks of exposure. Neurological effects were seen beginning at 10 weeks exposure. Motor nerve conduction velocity and distal latency were significantly affected after 4 weeks exposure. Examination of neural tissue showed damage to the tibial nerve and dorsal trunk of the tail nerve. The LOAEC for sub-chronic exposure was 3000 ppm (10560 mg/m^3). No NOAEC was found.
Reference
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- LOAEC
- 10 560 mg/m³
- Study duration:
- subchronic
- Species:
- rat
- Quality of whole database:
- 1 key substance specific study available for assessment
Effect on neurotoxicity: via dermal route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
A sub-chronic neurotoxicity study in rats is available for n-hexane. Additionally, occupational epidemiology data describing neurotoxicity effects in humans are available for n-hexane and have been extensively reviewed by WHO, the Agency for Toxic Substances and Disease Registry (ATSDR), and the U.S. Environmental Protection Agency (U.S. EPA).
n-Hexane, neurological effects in animals
In a key neurotoxicity study, seven rats were exposed to 3000 ppm of n-hexane vapors for 12 hrs a day for 16 weeks (Takeuchi, 1980; Klimisch score =2). Body weights and conduction velocity of the peripheral nerve of the tail was measured at 0, 4, 8, 12 and 16 weeks. At the end of the exposure period, two animals were sacrificed and the nerve tissue examined. Two animals died before the end of the exposure period. All animals showed reduced weight gain after 4 weeks of exposure. Neurological effects were seen beginning at 10 weeks exposure. Motor nerve conduction velocity and distal latency were significantly affected after 4 weeks exposure. Examination of neural tissue showed damage to the tibial nerve and dorsal trunk of the tail nerve. The LOAEC for sub-chronic exposure was 3000 ppm (10560 mg/m3). No NOAEC was found.
n-Hexane, neurological effects in humans
Among hydrocarbon solvents, a unique toxicological effect of n-hexane in humans is its association with pathological changes in the peripheral nervous system, more specifically an axonal neuropathy of the lower extremities. Development of the axonal neuropathy is the consequence of exposure to a neurotoxic metabolite of n-hexane; 2,4-hexanedione. Although questions have been raised regarding the potential for other hexane solvents, including other C6 isomers, to produce similar effects, it has been shown, primarily through animal models, that hydrocarbons other than n-hexane do not form the 2,5-hexanedione metabolite and, accordingly, do not produce similar neurological effects (see for example WHO, 1991; ATSDR, 1999, U.S. EPA, 2005).
The association of n-hexane exposure with the development of peripheral neuropathy was first described in studies of Japanese sandal workers. Based on assessment reviews of epidemiology studies of n-hexane (e.g., WHO, 1991, ATSDR, 1999, U.S. EPA, 2005) exposure estimates ranged from 1625 -8125 mg/m3 (500 – 2500 ppm), although these measurements were typically done after the fact. As additional complications, these workers typically worked very long hours and often lived in the same location. The cases were divided into 3 categories based on severity of the disease:
Group 1 Sensory neuropathy
Group II Sensorimotor neuropathy
Group III Motor neuropathy with amyotrophy
Studies of 95 employees at an Italian shoe factory population (Mutti et al., 1982) identified subclinical neuropathy, particularly significant reductions in nerve conduction velocity. The approximate average exposure to n-hexane in the work place was 317 mg/m3 (90 ppm) over a 2 year period. Additionally, other solvents were used. When these workers were subdivided into “low” (approximately 243 mg/m3) and “high” (approximately 475 mg/m3) exposure groups based on n-hexane levels, there appeared to be a dose-related trend.
A study of Taiwanese press proofers was reported by Wang et al. (1986). Fifteen cases of overt peripheral neuropathy were diagnosed among 59 workers distributed among 16 factories. The average levels of n-hexane exposure at the two factories, accounting for 8 of the 15 cases, were 669 mg/m3 and 74 mg/m3 respectively. It was also reported that workers typically worked more than 8 hours/day, and 12 of the 15 cases slept in the factories overnight. Exposure to n-hexane air concentrations less than 352 mg/m3 (100 ppm) was not associated with clinical peripheral neuropathy.
Due in part to concerns about the quality of the exposure measurements and differences in exposure periods, it has been difficult to establish thresholds for human effects. One recommendation is to use data on urinary levels of 2,5-hexanedione as a biomarker of exposure (SCOEL, 1995). Governa et al. (1987) reported that subclinical neurological effects were associated with urinary 2,5 hexanedione concentrations of > 7.5 mg/L whereas there were few effects among individuals with urinary levels 7.5 mg/L. Based data from Perbellini et al. (1981) relating urinary excretion of n-hexane metabolites with external n-hexane exposure, 7.5 mg/L corresponds to approximately 250 mg/m3 (70 ppm).
Assessment Review References:
ATSDR (Agency for Toxic Substances and Disease Registry) (1999). Toxicological Profile for n-Hexane. ATSDR, Atlanta, Georgia.
SCOEL (Scientific Committee on Occupational Exposure Limits) (1995). Recommendations from Scientific Expert Group on Occupational Exposure Limits for n-hexane. SEG/SUM/52C.
U.S. EPA (U.S. Environmental Protection Agency) (2005). Toxicological Review of n-Hexane (CAS No. 110 -54-3) In Support of Summary Information on the Integrated Risk Information System (IRIS). November 2005, U.S. Environmental Protection Agency Washington, DC. EPA/635/R-03/012.
WHO, International Program on Chemical Safety (1991). Environmental Health Criteria (EHC) 122, n-Hexane. World Health Organization, Geneva, Switzerland.
Justification for classification or non-classification
Based on the information presented in the study on anaesthetic activity of n-hexane, n-hexanes are classified as STOT Single Exp. 3 (H336: May cause drowsiness or dizziness) in accordance with CLP EU Regulation 1272/2008.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
